Advances in the Treatment and Management of MASH: More Options, More Decisions

Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and progressive. What’s most concerning is that MASLD/MASH will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Until recently there was no liver-directed therapy for this disease, and the metabolic benefits of pharmacologic modification of body weight were underappreciated. This activity will also provide practical interactive discussions of cardiometabolic pathophysiologic pathways; early identification and risk stratification; advances in treatment; monitoring for disease progression; and long-term medical management, including the role of incretin agonists.